KY-05009

KY-05009 (also known as NCB-0005) is a small molecule, ATP-competitive inhibitor of TRAF2 and NCK-interacting protein kinase (TNIK) with a Ki of 100 nM and an IC50 of 9 nM. Developed by Eulji University and the Korea Research Institute of Chemical Technology (KRICT), KY-05009 inhibits the kinase activity of TNIK, thereby suppressing the phosphorylation of TCF4 and the activation of the Wnt/β-catenin signaling pathway. It has been shown to attenuate transforming growth factor-beta 1 (TGF-β1)-induced epithelial-to-mesenchymal transition (EMT), migration, and invasion in lung adenocarcinoma cells, and to induce apoptosis in multiple myeloma cells. It is primarily used as a research tool to study Wnt signaling, EMT, and cytoskeletal reorganization.

Other names

5-(4-methylbenzamido)-2-(phenylamino)thiazole-4-carboxamide5-[(4-methylbenzoyl)amino]-2-(phenylamino)-4-thiazolecarboxamideKY 05009KY05009KY-05009